QIAGEN is expanding its Sample technologies portfolio with Parse Biosciences to deliver scalable single-cell solutions capable of handling millions to billions of cells, while enhancing QIAGEN Digital Insights (QDI) with AI-driven single-cell data capabilities.

Parse’s Evercode platform will enable AI-powered generation, processing, and interpretation of large-scale single-cell data without the need for instruments, accelerating QDI capabilities and research workflows.

The acquisition positions QIAGEN to enter the fast-growing single-cell sequencing market, leveraging Parse's technology to analyze vast cell numbers across multiple therapeutic areas.

The deal is subject to regulatory approvals and customary closing conditions, with an expected close in 2025 and anticipated 2026 sales contribution of about $40 million, though it will be dilutive to adjusted EPS in 2026 and accretive from 2028 onward.

Parse holds exclusive licenses to 36 University of Washington patents on split-pool combinatorial barcoding, providing strong IP protection for its technology.

Parse’s technology is already used by more than 3,000 labs worldwide, including top research institutions and pharma companies, with exclusive UW patent rights underpinning its platform.

QIAGEN has signed a definitive agreement to acquire Parse Biosciences for about $225 million in cash, with up to $55 million in potential milestone payments, with completion expected in December 2025.

The transaction will be completed on the stated timeline, subject to customary conditions and milestones, strengthening QIAGEN’s global reach and product portfolio.

Leadership from both companies emphasize the strategic fit, speed to scale, and global reach as core benefits of the acquisition.

Parse’s GigaLab service can process up to 2.5 billion cells per year and supports multi-million cell projects across oncology, immunology, and neurology.

Financial outlook notes Parse will contribute roughly $40 million in 2026 sales (about 2% growth) with strong double-digit growth thereafter, and the deal is dilutive to EPS in 2026 but accretive from 2028 onward.

Leadership statements highlight accelerating access to single-cell technology and building predictive virtual cell models to aid AI-driven drug discovery.